Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Astronomer captures 2 meteors slamming into the moon (video) - 2Find the Keys to Fruitful Venture The board: Conveying Results on Time
- 3I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- 4CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- 5Fundamental Monetary Guidance for Going into Business
- 4 DSLR Cameras for Amateurs in 2024
- Most loved Well known Accessory Styles For 2024
- Fundamental Home Machines for Improved Solace in Summer
- Compassion and Association: Building Significant Connections
- Genome study reveals milestone in history of cat domestication
- Which Kind of Pet Makes the Incomparable Buddy?
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
